CDT Equity (CDT) announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656, following positive data from pre-clinical studies. This affirms the Company’s decision to pursue an artificial intelligence-led drug repurposing strategy for its portfolio. CDT, in collaboration with Sarborg, has carried out an in-depth analysis of AZD1656, utilizing an algorithmic approach that involves AI-powered disease mapping to identify repurposing opportunities against a database of over 800 diseases signatures. This new approach identified several indications for AZD1656 in therapeutic areas previously not associated with this asset. With a robust patent portfolio already in place, CDT has initiated several pre-clinical studies to explore the potential of AZD1656 in these untapped therapeutic areas.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Rebrands to CDT Equity Inc.
- Conduit Pharmaceuticals to change name to CDT Equity
- Conduit Pharmaceuticals files to sell 255K shares of common stock for holders
- Conduit Pharmaceuticals to explore cryptocurrency reserve strategy
- Conduit Pharmaceuticals files four new patent applications